• Photocure initiated arbitration against Asieris over an unpaid portion of an $11 million milestone tied to APL-1702 (CEVIRA) approval in China.
• Asieris paid $6.6 million of the invoiced milestone, leaving $4.4 million in dispute.
• The milestone was triggered by Asieris receiving a Drug Registration Certificate from China’s National Medical Products Administration.
• Photocure continues discussions with Asieris while pursuing recovery through arbitration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.